511 related articles for article (PubMed ID: 25877016)
1. Clinical management of critically ill patients with Cushing's disease due to ACTH-secreting pituitary macroadenomas: effectiveness of presurgical treatment with pasireotide.
Cannavo S; Messina E; Albani A; Ferrau F; Barresi V; Priola S; Esposito F; Angileri F
Endocrine; 2016 Jun; 52(3):481-7. PubMed ID: 25877016
[TBL] [Abstract][Full Text] [Related]
2. Relapsing, remitting hypercortisolism in Cushing's disease due to intratumoral hemorrhages in pituitary microadenoma.
Marko NF; Hamrahian AH; Hatipoglu B; Weil RJ
J Clin Neurosci; 2013 May; 20(5):753-6. PubMed ID: 23352667
[TBL] [Abstract][Full Text] [Related]
3. Pituitary-directed medical therapy in Cushing's disease.
Petersenn S; Fleseriu M
Pituitary; 2015 Apr; 18(2):238-44. PubMed ID: 25627118
[TBL] [Abstract][Full Text] [Related]
4. The treatment with pasireotide in Cushing's disease: effects of long-term treatment on tumor mass in the experience of a single center.
Simeoli C; Auriemma RS; Tortora F; De Leo M; Iacuaniello D; Cozzolino A; De Martino MC; Pivonello C; Mainolfi CG; Rossi R; Cirillo S; Colao A; Pivonello R
Endocrine; 2015 Dec; 50(3):725-40. PubMed ID: 25743263
[TBL] [Abstract][Full Text] [Related]
5. Paradoxical and atypical responses to pasireotide in aggressive ACTH-secreting pituitary tumors.
Greenman Y; Stern N
Pituitary; 2016 Dec; 19(6):605-611. PubMed ID: 27639583
[TBL] [Abstract][Full Text] [Related]
6. Pituitary-directed medical therapy with pasireotide for a corticotroph macroadenoma: pituitary volume reduction and literature review.
Shimon I; Rot L; Inbar E
Pituitary; 2012 Dec; 15(4):608-13. PubMed ID: 22918543
[TBL] [Abstract][Full Text] [Related]
7. Somatostatin and somatostatin receptors in Cushing's disease.
Hofland LJ
Mol Cell Endocrinol; 2008 May; 286(1-2):199-205. PubMed ID: 18221833
[TBL] [Abstract][Full Text] [Related]
8. Temozolomide therapy for aggressive pituitary Crooke's cell corticotropinoma causing Cushing's Disease - a case report with literature review.
Gilis-Januszewska A; Wilusz M; Pantofliński J; Turek-Jabrocka R; Sokołowski G; Sowa-Staszczak A; Kluczyński Ł; Pach D; Zieliński G; Hubalewska-Dydejczyk A
Endokrynol Pol; 2018; 69(3):306-312. PubMed ID: 29319131
[TBL] [Abstract][Full Text] [Related]
9. Preoperative normalization of cortisol levels in Cushing's disease after medical treatment: consequences for somatostatin and dopamine receptor subtype expression and in vitro response to somatostatin analogs and dopamine agonists.
van der Pas R; Feelders RA; Gatto F; de Bruin C; Pereira AM; van Koetsveld PM; Sprij-Mooij DM; Waaijers AM; Dogan F; Schulz S; Kros JM; Lamberts SW; Hofland LJ
J Clin Endocrinol Metab; 2013 Dec; 98(12):E1880-90. PubMed ID: 24081741
[TBL] [Abstract][Full Text] [Related]
10. [Predictors of long-term remission after transsphenoidal surgery in Cushing's disease].
Abellán Galiana P; Fajardo Montañana C; Riesgo Suárez PA; Gómez Vela J; Escrivá CM; Lillo VR
Endocrinol Nutr; 2013 Oct; 60(8):475-82. PubMed ID: 23266144
[TBL] [Abstract][Full Text] [Related]
11. Medical treatment of Cushing's disease: somatostatin analogues and pasireotide.
Pedroncelli AM
Neuroendocrinology; 2010; 92 Suppl 1():120-4. PubMed ID: 20829632
[TBL] [Abstract][Full Text] [Related]
12. Treatment of pituitary-dependent Cushing's disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial.
Boscaro M; Ludlam WH; Atkinson B; Glusman JE; Petersenn S; Reincke M; Snyder P; Tabarin A; Biller BM; Findling J; Melmed S; Darby CH; Hu K; Wang Y; Freda PU; Grossman AB; Frohman LA; Bertherat J
J Clin Endocrinol Metab; 2009 Jan; 94(1):115-22. PubMed ID: 18957506
[TBL] [Abstract][Full Text] [Related]
13. Surgical management of adrenocorticotropic hormone-secreting macroadenomas: outcome and challenges in patients with Cushing's disease or Nelson's syndrome.
De Tommasi C; Vance ML; Okonkwo DO; Diallo A; Laws ER
J Neurosurg; 2005 Nov; 103(5):825-30. PubMed ID: 16304985
[TBL] [Abstract][Full Text] [Related]
14. Cushing's disease: current medical therapies and molecular insights guiding future therapies.
Lau D; Rutledge C; Aghi MK
Neurosurg Focus; 2015 Feb; 38(2):E11. PubMed ID: 25639313
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Factors of Long-Term Remission After Surgical Treatment of Cushing's Disease.
Ioachimescu AG
Endocrinol Metab Clin North Am; 2018 Jun; 47(2):335-347. PubMed ID: 29754635
[TBL] [Abstract][Full Text] [Related]
16. Tumor-Directed Therapeutic Targets in Cushing Disease.
Theodoropoulou M; Reincke M
J Clin Endocrinol Metab; 2019 Mar; 104(3):925-933. PubMed ID: 30535260
[TBL] [Abstract][Full Text] [Related]
17. Medical combination therapies in Cushing's disease.
Vilar L; Naves LA; Machado MC; Bronstein MD
Pituitary; 2015 Apr; 18(2):253-62. PubMed ID: 25647330
[TBL] [Abstract][Full Text] [Related]
18. Safety of transsphenoidal microsurgical approach in patients with an ACTH-secreting pituitary adenoma.
Donofrio CA; Losa M; Gemma M; Giudice L; Barzaghi LR; Mortini P
Endocrine; 2017 Nov; 58(2):303-311. PubMed ID: 28005257
[TBL] [Abstract][Full Text] [Related]
19. Complications after transsphenoidal surgery for patients with Cushing's disease and silent corticotroph adenomas.
Smith TR; Hulou MM; Huang KT; Nery B; de Moura SM; Cote DJ; Laws ER
Neurosurg Focus; 2015 Feb; 38(2):E12. PubMed ID: 25639314
[TBL] [Abstract][Full Text] [Related]
20. Pasireotide.
Feelders RA; Yasothan U; Kirkpatrick P
Nat Rev Drug Discov; 2012 Aug; 11(8):597-8. PubMed ID: 22850776
[No Abstract] [Full Text] [Related]
[Next] [New Search]
